Skip to main content

Insulin regular Disease Interactions

There are 3 disease interactions with insulin regular.

Moderate

Insulin (applies to insulin regular) renal/liver disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis. Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.

References

  1. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  2. "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals (2001):
  3. "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc (2022):
  4. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals (2004):
  5. "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc (2005):
  6. "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation (2014):
  7. "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):
View all 7 references
Moderate

Insulin- hypokalemia

Moderate Potential Hazard, Moderate plausibility.

Hypokalemia may commonly occur during treatment with insulin. Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

References

  1. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  2. "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals (2001):
  3. "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc (2022):
  4. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals (2004):
  5. "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc (2005):
  6. "Product Information. Afrezza (insulin inhalation, rapid acting)." MannKind Corporation (2014):
  7. "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):
View all 7 references
Moderate

Insulin/oral hypoglycemic agents (applies to insulin regular) hypoglycemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems

Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.

References

  1. "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals (2002):
  2. "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals (2002):
  3. "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  4. "Product Information. Micronase (glyburide)." Pharmacia and Upjohn (2002):
  5. "Multum Information Services, Inc. Expert Review Panel"
  6. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  7. "Product Information. Glucophage (metformin)." Bristol-Myers Squibb (2001):
  8. "Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel (2001):
  9. "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc (2001):
  10. Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
  11. "Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn (2001):
  12. "Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company (2001):
  13. "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals (2001):
  14. "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc (2022):
  15. "Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals (2001):
  16. "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals (2004):
  17. "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc (2005):
  18. "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc (2015):
View all 18 references

Insulin regular drug interactions

There are 377 drug interactions with insulin regular.

Insulin regular alcohol/food interactions

There is 1 alcohol/food interaction with insulin regular.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.